LncRNA-CCAT5-mediated crosstalk between Wnt/β-Catenin and STAT3 signaling suggests novel therapeutic approaches for metastatic gastric cancer with high Wnt activity

Abstract

Background: Although the constitutively activated Wnt/β-catenin signaling pathway plays vital roles in gastric cancer (GC) progression, few Wnt inhibitors are approved for clinical use. Additionally, the clinical significance of long non-coding RNAs (lncRNAs) in GC intraperitoneal dissemination (IPD) remains elusive. Here, we investigated the function and therapeutic potential of Wnt-transactivated lncRNA, colon cancer-associated transcript 5 (CCAT5), in GC metastasis.

Methods: LncRNA-sequencing assay was performed to document abundance changes of lncRNAs induced by Wnt family member 3A (Wnt3a) and degradation-resistant β-catenin (S33Y mutated) in ascites-derived GC cells with low Wnt activity. Luciferase reporter, Chromatin immunoprecipitation (ChIP)-re-ChIP assays were performed to determine how CCAT5 was transcribed. The clinical significance of CCAT5 was examined in 2 cohorts of GC patients. The biological function of CCAT5 was investigated through gain-and loss-of-function studies. The molecular mechanism was explored through RNA-sequencing, mass spectrometry, and CRISPR/Cas9-knocknout system. The therapeutic potential of CCAT5 was examined through RNAi-based cell xenograft model and patient-derived xenograft (PDX) model of IPD.

Results: We identified a novel Wnt-regulated lncRNA, CCAT5, which was transactivated by the β-catenin/transcription factor 3 (TCF3) complex. CCAT5 was significantly upregulated in GC and predicted poor prognosis. Functional studies confirmed the promotive role of CCAT5 in GC growth and metastasis. Mechanistically, CCAT5 bound to the C-end domain of signal transducer and activator of transcription 3 (STAT3) and blocks Src homology 2 domain-containing protein tyrosine phosphatase 1 (SHP-1)-mediated STAT3^Y705 dephosphorylation, leading to STAT3 nuclear entry and transactivation, thus accelerating GC progression. Furthermore, we demonstrated that both Wnt3a and β-catenin acted as activator of STAT3 signaling pathway, and the interplay between CCAT5 and STAT3 was functionally essential for Wnt-drived STAT3 signaling and tumor evolution. Finally, we revealed in vivo si-CCAT5 selectively attenuated growth and metastasis of Wnt^high GC, but not Wnt^low GC. The combination of si-CCAT5 and oxaliplatin displayed obvious synergistic therapeutic effects on Wnt^high PDX mice.

Conclusions: We identified a novel Wnt-transactivated lncRNA, CCAT5. Our study revealed a mechanism of STAT3 signaling regulation via canonical Wnt signaling and the functional significance of CCAT5 as critical mediator. We provided conceptual advance that lncRNAs serve as therapeutic targets reversing GC progression.

Keywords

CCAT5 / gastric cancer / intraperitoneal dissemination / STAT3 / Wnt/β-catenin

References

[1] SmythEC, Nilsson M, GrabschHI, van GriekenNC, Lordick F. Gastric cancer. Lancet. 2020;396(10251):635-648.

[2] QiuH, CaoS, XuR. Cancer incidence, mortality, and burden in China: a time-trend analysis and comparison with the United States and United Kingdom based on the global epidemiological data released in 2020. Cancer Commun (Lond). 2021;41(10):1037-1048.

[3] GunerA, Yildirim R. Surgical management of metastatic gastric cancer: moving beyond the guidelines. Transl Gastroenterol Hepatol. 2019;4:58.

[4] ChiaDKA, SoJBY. Recent Advances in Intra-peritoneal Chemotherapy for Gastric Cancer. J Gastric Cancer. 2020;20(2):115-126.

[5] OoiCH, Ivanova T, WuJ, LeeM, TanIB, TaoJ, et al. Oncogenic pathway combinations predict clinical prognosis in gastric cancer. PLoS Genet. 2009;5(10):e1000676.

[6] WangK, YuenST, XuJ, LeeSP, YanHH, Shi ST, et al. Whole-genome sequencing and comprehensive molecular profiling identify new driver mutations in gastric cancer. Nat Genet. 2014;46(6):573-582.

[7] KoushyarS, PowellAG, VincanE, Phesse TJ. Targeting Wnt Signaling for the Treatment of Gastric Cancer. Int J Mol Sci. 2020;21(11):3927.

[8] HeubergerJ, Birchmeier W. Interplay of cadherin-mediated cell adhesion and canonical Wnt signaling. Cold Spring Harb Perspect Biol. 2010;2(2):a002915.

[9] ZhanT, Rindtorff N, BoutrosM. Wnt signaling in cancer. Oncogene. 2017;36(11):1461-1473.

[10] JiangX, CongF. Novel Regulation of Wnt Signaling at the Proximal Membrane Level. Trends Biochem Sci. 2016;41(9):773-783.

[11] Ter SteegeEJ, BakkerERM. The role of R-spondin proteins in cancer biology. Oncogene. 2021;40(47):6469-6478.

[12] ParkHW, KimYC, YuB, Moroishi T, MoJS, PlouffeSW, et al. Alternative Wnt Signaling Activates YAP/TAZ. Cell. 2015;162(4):780-794.

[13] RosenbluhJ, Nijhawan D, CoxAG, LiX, NealJT, SchaferEJ, et al. β-Catenin-driven cancers require a YAP1 transcriptional complex for survival and tumorigenesis. Cell. 2012;151(7):1457-1473.

[14] LeeG, Goretsky T, ManagliaE, DirisinaR, SinghAP, BrownJB, et al. Phosphoinositide 3-kinase signaling mediates beta-catenin activation in intestinal epithelial stem and progenitor cells in colitis. Gastroenterology. 2010;139(3):869-881, 81.e1-9.

[15] van AndelH, RenZ, KoopmansI, Joosten SP, KocembaKA, de LauW, et al. Aberrantly expressed LGR4 empowers Wnt signaling in multiple myeloma by hijacking osteoblast-derived R-spondins. Proc Natl Acad Sci U S A. 2017;114(2):376-381.

[16] YuanL, XuZY, RuanSM, Mo S, QinJJ, ChengXD. Long non-coding RNAs towards precision medicine in gastric cancer: early diagnosis, treatment, and drug resistance. Mol Cancer. 2020;19(1):96.

[17] PengWX, Koirala P, MoYY. LncRNA-mediated regulation of cell signaling in cancer. Oncogene. 2017;36(41):5661-5667.

[18] TanYT, LinJF, LiT, LiJJ, XuRH, JuHQ. LncRNA-mediated posttranslational modifications and reprogramming of energy metabolism in cancer. Cancer Commun (Lond). 2021;41(2):109-120.

[19] GaoY, WangJW, RenJY, Guo M, GuoCW, NingSW, et al. Long noncoding RNAs in gastric cancer: From molecular dissection to clinical application. World J Gastroenterol. 2020;26(24):3401-3412.

[20] LinC, YangL. Long Noncoding RNA in Cancer: Wiring Signaling Circuitry. Trends Cell Biol. 2018;28(4):287-301.

[21] JungYS, ParkJI. Wnt signaling in cancer: therapeutic targeting of Wnt signaling beyond β-catenin and the destruction complex. Exp Mol Med. 2020;52(2):183-191.

[22] ZhangX, WangL, QuY. Targeting the β-catenin signaling for cancer therapy. Pharmacol Res. 2020;160:104794.

[23] InceTA, SousaAD, JonesMA, Harrell JC, AgostonES, KrohnM, et al. Characterization of twenty-five ovarian tumour cell lines that phenocopy primary tumours. Nat Commun. 2015;6:7419.

[24] SmootDT, Sewchand J, YoungK, DesbordesBC, AllenCR, NaabT. A method for establishing primary cultures of human gastric epithelial cells. Methods Cell Sci. 2000;22(2-3):133-136.

[25] AjaniJA, XuY, HuoL, WangR, LiY, WangY, et al. YAP1 mediates gastric adenocarcinoma peritoneal metastases that are attenuated by YAP1 inhibition. Gut. 2020;70(1):55-66.

[26] Furlan-MagarilM, Rincon-Arano H, Recillas-TargaF. Sequential chromatin immunoprecipitation protocol: ChIP-reChIP. Methods Mol Biol. 2009;543:253-266.

[27] YueB, LiuC, SunH, LiuM, SongC, Cui R, et al. A Positive Feed-Forward Loop between LncRNA-CYTOR and Wnt/beta-Catenin Signaling Promotes Metastasis of Colon Cancer. Mol Ther. 2018;26(5):1287-1298.

[28] LuanH, YanL, ZhaoY, Ding X, CaoL. Fucoxanthin induces apoptosis and reverses epithelial-mesenchymal transition via inhibiting Wnt/β-catenin pathway in lung adenocarcinoma. Discov Oncol. 2022;13(1):98.

[29] SprangerS, BaoR, GajewskiTF. Melanoma-intrinsic β-catenin signalling prevents anti-tumour immunity. Nature. 2015;523(7559):231-235.

[30] ZhangH, XuR, LiB, XinZ, LingZ, Zhu W, et al. LncRNA NEAT1 controls the lineage fates of BMSCs during skeletal aging by impairing mitochondrial function and pluripotency maintenance. Cell Death Differ. 2022;29(2):351-365.

[31] ColeMF, Johnstone SE, NewmanJJ, KageyMH, YoungRA. Tcf3 is an integral component of the core regulatory circuitry of embryonic stem cells. Genes Dev. 2008;22(6):746-755.

[32] YuH, LeeH, HerrmannA, Buettner R, JoveR. Revisiting STAT3 signalling in cancer: new and unexpected biological functions. Nat Rev Cancer. 2014;14(11):736-746.

[33] SchmittAM, ChangHY. Long Noncoding RNAs in Cancer Pathways. Cancer Cell. 2016;29(4):452-463.

[34] BuchertM, BurnsCJ, ErnstM. Targeting JAK kinase in solid tumors: emerging opportunities and challenges. Oncogene. 2016;35(8):939-951.

[35] YuanJ, ZhangF, NiuR. Multiple regulation pathways and pivotal biological functions of STAT3 in cancer. Sci Rep. 2015;5:17663.

[36] HuangTT, SuJC, LiuCY, Shiau CW, ChenKF. Alteration of SHP-1/p-STAT3 Signaling: A Potential Target for Anticancer Therapy. Int J Mol Sci. 2017;18(6):1234.

[37] FengY, RenJ, GuiY, WeiW, ShuB, LuQ, et al. Wnt/beta-Catenin-Promoted Macrophage Alternative Activation Contributes to Kidney Fibrosis. J Am Soc Nephrol. 2018;29(1):182-193.

[38] FragosoMA, PatelAK, NakamuraRE, Yi H, SurapaneniK, HackamAS. The Wnt/beta-catenin pathway cross-talks with STAT3 signaling to regulate survival of retinal pigment epithelium cells. PLoS One. 2012;7(10):e46892.

[39] YangG, ShenT, YiX, ZhangZ, TangC, Wang L, et al. Crosstalk between long non-coding RNAs and Wnt/β-catenin signalling in cancer. J Cell Mol Med. 2018;22(4):2062-2070.

[40] ZarkouV, Galaras A, GiakountisA, HatzisP. Crosstalk mechanisms between the WNT signaling pathway and long non-coding RNAs. Noncoding RNA Res. 2018;3(2):42-53.

[41] HuXY, HouPF, LiTT, QuanHY, LiML, LinT, et al. The roles of Wnt/β-catenin signaling pathway related lncRNAs in cancer. Int J Biol Sci. 2018;14(14):2003-2011.

[42] MaY, YangY, WangF, Moyer MP, WeiQ, ZhangP, et al. Long non-coding RNA CCAL regulates colorectal cancer progression by activating Wnt/β-catenin signalling pathway via suppression of activator protein 2α. Gut. 2016;65(9):1494-1504.

[43] LuY, ZhaoX, LiuQ, LiC, Graves-DealR, CaoZ, et al. lncRNA MIR100HG-derived miR-100 and miR-125b mediate cetuximab resistance via Wnt/β-catenin signaling. Nat Med. 2017;23(11):1331-1341.

[44] WangY, HeL, DuY, ZhuP, HuangG, Luo J, et al. The long noncoding RNA lncTCF7 promotes self-renewal of human liver cancer stem cells through activation of Wnt signaling. Cell Stem Cell. 2015;16(4):413-425.

[45] WuZH, LiuCC, ZhouYQ, Hu LN, GuoWJ. OnclncRNA-626 promotes malignancy of gastric cancer via inactivated the p53 pathway through interacting with SRSF1. Am J Cancer Res. 2019;9(10):2249-2263.

[46] LiC, WangS, XingZ, Lin A, LiangK, SongJ, et al. A ROR1-HER3-lncRNA signalling axis modulates the Hippo-YAP pathway to regulate bone metastasis. Mol Cell Biol. 2017;19(2):106-119.

[47] LvY, LiH, LiF, LiuP, ZhaoX. Long Noncoding RNA MNX1-AS1 Knockdown Inhibits Cell Proliferation and Migration in Ovarian Cancer. Cancer Biother Radiopharm. 2017;32(3):91-99.

[48] ZhaoX, LiX, ZhouL, Ni J, YanW, MaR, et al. LncRNA HOXA11-AS drives cisplatin resistance of human LUAD cells via modulating miR-454-3p/Stat3. Cancer Science. 2018;109(10):3068-3079.

[49] ZhaoW, FuH, ZhangS, Sun S, LiuY. LncRNA SNHG16 drives proliferation, migration, and invasion of hemangioma endothelial cell through modulation of miR-520d-3p/STAT3 axis. Cancer Med. 2018;7(7):3311-3320.

[50] ChuJ, LiH, XingY, Jia J, ShengJ, YangL, et al. LncRNA MNX1-AS1 promotes progression of esophageal squamous cell carcinoma by regulating miR-34a/SIRT1 axis. Biomed Pharmacother. 2019;116:109029.

[51] JiD, WangY, SunB, YangJ, LuoX. Long non-coding RNA MNX1-AS1 promotes hepatocellular carcinoma proliferation and invasion through targeting miR-218-5p/COMMD8 axis. Biochem Biophys Res Commun. 2019;513(3):669-674.

[52] ShuaiY, MaZ, LiuW, YuT, YanC, JiangH, et al. TEAD4 modulated LncRNA MNX1-AS1 contributes to gastric cancer progression partly through suppressing BTG2 and activating BCL2. Mol Cancer. 2020;19(1):6.

[53] CuiX, YuH, YuT, XiaoD, WangX. LncRNA MNX1-AS1 drives aggressive laryngeal squamous cell carcinoma progression and serves as a ceRNA to target FoxM1 by sponging microRNA-370. Aging (Albany NY). 2021;13(7):9900-9910.

[54] MaB, RenG, XuJ, YinC, ShiY. LncRNA MNX1-AS1 Contributes to Laryngeal Squamous Cell Carcinoma Growth and Migration by Regulating mir-744-5p/bcl9/β-Catenin Axis. Cell Transplant. 2021;30:9636897211005682.

[55] WuQN, LuoXJ, LiuJ, LuYX, WangY, Qi J, et al. MYC-Activated LncRNA MNX1-AS1 Promotes the Progression of Colorectal Cancer by Stabilizing YB1. Cancer Res. 2021;81(10):2636-2650.

[56] PichlerM, Rodriguez-Aguayo C, NamSY, DragomirMP, Bayraktar R, AnfossiS, et al. Therapeutic potential of FLANC, a novel primate-specific long non-coding RNA in colorectal cancer. Gut. 2020;69(10):1818-1831.

[57] ZhuoW, LiuY, LiS, GuoD, SunQ, JinJ, et al. Long Noncoding RNA GMAN, Up-regulated in Gastric Cancer Tissues, Is Associated With Metastasis in Patients and Promotes Translation of Ephrin A1 by Competitively Binding GMAN-AS. Gastroenterology. 2019;156(3):676-691.e11.

RIGHTS & PERMISSIONS

2023 2023 The Authors. Cancer Communications published by JohnWiley & Sons Australia, Ltd on behalf of SUN YAT-SEN UNIVERSITY CANCER CENTER.